Hong Kong begins Covid vaccinations for 7.5 mn residents with Sinovac jab

A poll published in January by the University of Hong Kong found respondents concerned about the Chinese vaccine''s efficacy

Coronavirus
A woman wearing a face mask as a precaution against the COVID-19 while using smartphone in a subway train in Hong Kong | PTI
AP Hong Kong
2 min read Last Updated : Feb 26 2021 | 8:45 AM IST

Hong Kong began administering its first COVID-19 vaccines to the public Friday, kicking off its program offering free vaccinations to all 7.5 million residents.

People age 60 and older and health care workers are among the some 2.4 million people currently prioritized to receive vaccines at community centers and outpatient clinics across Hong Kong. The government said registrations for the first two weeks of the program are full.

Participants so far will be receiving the vaccine by Chinese biopharmaceutical firm Sinovac. A million doses arrived in the city last week, and Hong Kong leader Carrie Lam and other top government officials were vaccinated first in a bid to bolster confidence in the program.

A poll published in January by the University of Hong Kong found respondents concerned about the Chinese vaccine's efficacy.

A panel of Hong Kong experts said the efficacy of the Sinovac vaccine after two doses, 21 days apart, was 62.3 per cent. In contrast, a study in Israel found that the two-dose Pfizer-BioNTech vaccine has 92 per cent effectiveness.

Hong Kong has since struck deals to buy a total of 22.5 million doses of vaccines, with 7.5 million shots each from Sinovac, AstraZeneca and Fosun Pharma, which will deliver the Pfizer-BioNTech vaccines to the city.

The government has so far approved the Sinovac and Pfizer-BioNTech vaccines. The first million doses of the Pfizer-BioNTech vaccine was slated to arrive Thursday but has been delayed by export procedures, the government said in a statement.

Local newspaper South China Morning Post reported they were now due to arrive Saturday at the earliest.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusHong KongCoronavirus Vaccine

First Published: Feb 26 2021 | 8:41 AM IST

Next Story